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ACLD

:   advanced chronic liver disease

ALD

:   alcohol‐related liver disease

AUROC

:   area under the receiver operating characteristics

AVB

:   acute variceal bleeding

cACLD

:   compensated ACLD

CSPH

:   clinically significant portal hypertension

CTP

:   Child‐Turcotte‐Pugh

dACLD

:   decompensated ACLD

ELF

:   enhanced liver fibrosis score

HA

:   hyaluronic acid

HCV

:   viral hepatitis C

HRPH

:   high‐risk portal hypertension

HVPG

:   hepatic venous pressure gradient

INR

:   international normalized ratio

IVD

:   in vitro diagnostic

MELD

:   model for end‐stage liver disease

NAFLD

:   non‐alcoholic fatty liver disease

NASH

:   non‐alcoholic steatohepatitis

NLR

:   negative likelihood ratio

NPV

:   negative predictive value

NSBB

:   non‐selective beta‐blockers

PHT

:   portal hypertension

PIIINP

:   Amino‐terminal propeptide of type III procollagen

PLR

:   positive likelihood ratio

PLT

:   platelet

PPV

:   positive predictive value

TIMP‐1

:   tissue inhibitor matrix metalloproteinase‐1

TIPS

:   transjugular intrahepatic portosystemic shunt

VCTE

:   vibration‐controlled transient elastography

Key pointsPatients with liver disease may develop increased pressure in the blood vessels that drain into the liver. This condition is termed portal hypertension (PHT). Invasive catheter measurements must be performed to diagnose PHT. Our study shows that a simple blood test named "enhanced liver fibrosis (ELF) score" can identify patients with a high *versus* a low likelihood of suffering from PHT.

1. INTRODUCTION {#liv14498-sec-0006}
===============

Chronic liver injury causes liver damage that is characterized by necroinflammation and fibrosis, which can ultimately progress towards advanced chronic liver disease (ACLD; ie advanced liver fibrosis and cirrhosis). Perpetual increase in intrahepatic resistance finally results in development of portal hypertension (PHT).[^1^](#liv14498-bib-0001){ref-type="ref"} Hepatic venous pressure gradient (HVPG) above or equal to 10 mm Hg defines the presence of clinically significant portal hypertension (CSPH) and is assessed by hepatic vein catheterization.[^2^](#liv14498-bib-0002){ref-type="ref"} CSPH is an important prerequisite for the development of complications in patients with ACLD. Most importantly, patients with CSPH are at risk of hepatic decompensation and increased mortality.[^2^](#liv14498-bib-0002){ref-type="ref"}, [^3^](#liv14498-bib-0003){ref-type="ref"}

The enhanced liver fibrosis (ELF) score was firstly described to non‐invasively detect fibrosis in patients with non‐alcoholic fatty liver disease (NAFLD),[^4^](#liv14498-bib-0004){ref-type="ref"} and subsequently validated for viral hepatitis C (HCV)[^5^](#liv14498-bib-0005){ref-type="ref"} and is based on combining serum markers of matrix remodelling and fibrosis.[^6^](#liv14498-bib-0006){ref-type="ref"} The ELF score includes three single components, ie tissue inhibitor of matrix metalloproteinases (TIMP1), aminoterminal peptide of procollagen type III (PIIINP) and hyaluronic acid (HA).[^5^](#liv14498-bib-0005){ref-type="ref"} Ultimately, ELF score cut‐offs were proposed for the discrimination of patients with fibrosis from healthy individuals and for staging fibrosis in patients with HCV,[^5^](#liv14498-bib-0005){ref-type="ref"}, [^7^](#liv14498-bib-0007){ref-type="ref"} non‐alcoholic steatohepatitis (NASH),[^8^](#liv14498-bib-0008){ref-type="ref"} alcohol‐related liver disease (ALD)[^9^](#liv14498-bib-0009){ref-type="ref"} and paediatric NAFLD[^10^](#liv14498-bib-0010){ref-type="ref"} patients. Importantly, multiple studies reported that ELF was a predictor of disease progression and mortality.[^11^](#liv14498-bib-0011){ref-type="ref"}, [^12^](#liv14498-bib-0012){ref-type="ref"}, [^13^](#liv14498-bib-0013){ref-type="ref"}, [^14^](#liv14498-bib-0014){ref-type="ref"}

Previous studies assessing the ability of ELF score to detect CSPH have produced controversial results.[^15^](#liv14498-bib-0015){ref-type="ref"}, [^16^](#liv14498-bib-0016){ref-type="ref"}, [^17^](#liv14498-bib-0017){ref-type="ref"} In one of these studies, Sandahl et al computed a prediction model for CSPH by combining ELF with serum concentrations of soluble CD163, a serum marker of activated macrophages, which yielded in a higher accuracy in discriminating CSPH from subclinical PHT,[^16^](#liv14498-bib-0016){ref-type="ref"} as compared to ELF alone. Importantly, both ELF score and histological fibrosis stage as well as HVPG significantly decreased after cure from HCV in patients with PHT suggesting a correlation between the decline in HVPG and fibrosis that may be mirrored by changes in ELF score.[^17^](#liv14498-bib-0017){ref-type="ref"} The varying accuracy of ELF score to predict CSPH in previous studies may derive from considerable differences in the respective study cohorts such as liver disease aetiology, as well as severity of liver disease and of PHT. Finally, previous studies included both compensated and decompensated patients. However, the non‐invasive detection of CSPH is particularly relevant in patients with compensated ACLD (cACLD),[^18^](#liv14498-bib-0018){ref-type="ref"} who have not been analysed separately yet.

The aim of this study was to investigate the performance of ELF score to predict CSPH and high‐risk PHT (HRPH; ie HVPG ≥20 mm Hg) in a large prospective cohort of patients undergoing HVPG measurements and simultaneous assessment of ELF score.

2. PATIENTS AND METHODS {#liv14498-sec-0007}
=======================

2.1. Study design {#liv14498-sec-0008}
-----------------

A total of 201 patients with clinically stable ACLD undergoing hepatic vein catheterization between January 2017 and August 2019 at the Vienna Hepatic Hemodynamic Lab of the Medical University of Vienna were consecutively included in the prospective Vienna Cirrhosis Study (VICIS) (NCT03267615). Referral to HVPG measurement was based on reasonable suspicion of ACLD as a result of radiological and laboratory results and/or previous clinical symptoms associated with PHT according to national and international consensus recommendations.[^19^](#liv14498-bib-0019){ref-type="ref"}, [^20^](#liv14498-bib-0020){ref-type="ref"}

Patients with pre‐ or post‐hepatic causes of PHT, non‐cirrhotic PHT, hepatocellular carcinoma beyond Milan criteria, acute decompensation or non‐elective hospitalization, liver metastases or a history of transjugular intrahepatic portosystemic shunt (TIPS) implantation or liver transplantation were excluded (Figure [S1](#liv14498-sup-0001){ref-type="supplementary-material"}). Patients receiving concomitant treatment with non‐selective beta‐blockers were not included in the analysis. More specifically, patients either had never received non‐selective beta‐blockers (NSBB) or paused NSBB intake at least 5 days before HVPG measurement. Relevant clinical information and laboratory parameters were collected from patients' medical records. cACLD was defined as the absence of decompensating events prior to or at the time point of HVPG measurement, ie ascites, hepatic encephalopathy and variceal bleeding.[^21^](#liv14498-bib-0021){ref-type="ref"} Furthermore, vibration‐controlled transient elastography (VCTE; Fibroscan®) was performed instantaneously prior to HVPG measurement and considered for analysis when meeting reliability criteria as previously published.[^22^](#liv14498-bib-0022){ref-type="ref"}

2.2. HVPG measurements {#liv14498-sec-0009}
----------------------

HVPG measurements were performed by trained physicians of the Vienna Hepatic Hemodynamic Lab following a defined standard operating procedure[^23^](#liv14498-bib-0023){ref-type="ref"} in fasted condition. Briefly, the right internal jugular vein was punctured by ultrasound guidance under local anaesthesia. A catheter introducer set (8.5 F, Arrow International) was inserted using Seldinger technique. The liver vein was cannulated by an angled balloon occlusion catheter (Medical University of Vienna/Medizintechnik Pejcl, Austria).[^24^](#liv14498-bib-0024){ref-type="ref"} Adequate placement and wedge position were verified by X‐ray after injection of contrast agent while the balloon was inflated. At least three measurements of free and wedged hepatic vein pressure were performed to assess HVPG. No adverse events requiring medical intervention were recorded for patients included in this study.

2.3. Analysis of ELF score components {#liv14498-sec-0010}
-------------------------------------

The components of the ELF score (TIMP1, HA, PIIINP) were measured in serum---obtained from the catheter introducer sheath placed in the internal jugular vein during HVPG measurements---by in vitro diagnostic CE‐certified chemiluminescence immunoassays using the respective assay kits on an Advia Centaur CP analyser (Siemens Healthcare Diagnostics Inc) in an ISO 15189 accredited laboratory at the Department of Laboratory Medicine, Medical University of Vienna. The measurement ranges were for TIMP1 3.5‐1300 ng/mL, for HA 1.6‐1000 ng/mL, and for PIIINP 0.5‐150 ng/mL. The total coefficients of variation according to CLSI Guideline EP5‐A2 were ≤6.0, ≤7.7 and ≤6.5 for TIMP1, HA and PIIINP respectively.

The final score was calculated as previously reported[^5^](#liv14498-bib-0005){ref-type="ref"}: ELF score = 2.494 + 0.846 ln(C~HA~) + 0.735 ln(C~PIIINP~) + 0.391 ln(C~TIMP1~). ELF component measurements were performed by technicians at the department of Laboratory Medicine at the Medical University of Vienna blinded to the clinical and hemodynamic data of the subjects.

2.4. Statistics {#liv14498-sec-0011}
---------------

Statistical analyses were performed using [ibm spss]{.smallcaps} Statistics 26 (IBM) and GraphPad Prism 8 (GraphPad Software). Continuous variables are reported as mean ± standard error of the mean (SEM) or median and IQR, and categorical variables are presented as numbers (n) and proportions (%) of patients. Comparisons of continuous variables were performed using Student\'s t‐test or Mann‐Whitney *U* test, as applicable. Categorical variables were compared with chi‐squared or Fisher's exact test, as applicable. Receiver operating characteristic (ROC) curves were used to test the performance of ELF score to detect CSPH. Additionally, we assessed area under the receiver operating characteristics (AUROC), sensitivity, specificity, positive (PPV) and negative (NPV) predictive values, as well as positive (PLR) and negative (NLR) likelihood ratios for the detection of CSPH and HRPH. The optimal cut‐off values were evaluated by Youden\'s index (sensitivity + specificity −1), whereas most inclusive cut‐offs achieving a sensitivity or specificity ≥90% were chosen for ruling‐out and ruling‐in CSPH and HRPH respectively. Furthermore, exploratory AUROC analyses were performed in subgroups of different disease aetiologies and patients with cACLD. A two‐sided *P* ≤ .05 was defined to denote statistical significance.

2.5. Ethics {#liv14498-sec-0012}
-----------

This study was conducted in accordance with the 1964 Helsinki declaration and its later amendments and approved by the local ethics committee of the Medical University of Vienna (EK1262/2017). All patients gave written informed consent to liver vein catheterizations and provided written consent to be enrolled in the VICIS study (NCT03267615). Study results are reported according to STARD guidelines for diagnostic studies ([https://www.equator‐network.org/reporting‐guidelines/stard/](https://www.equator-network.org/reporting-guidelines/stard/)).

3. RESULTS {#liv14498-sec-0013}
==========

3.1. Patient characteristics {#liv14498-sec-0014}
----------------------------

The majority of patients in our study cohort were male (n = 135/201, 67%), and the prevalence of CSPH and HRPH was 88% (177/201) and 32% (65/201) respectively. ALD (n = 83, 41%) and viral hepatitis (n = 40, 20%) were the most common aetiologies of ACLD. The mean age was 56.8 ± 0.8 years (Table [S1](#liv14498-sup-0001){ref-type="supplementary-material"}). Eighty‐five (42%) patients presented with cACLD (including n = 62, 73% with CSPH). Most patients (58%) had Child‐Turcotte‐Pugh (CTP) stage A, while 33% had CTP stage B and 9% had CTP stage C. Median model for end‐stage liver disease (MELD) score was 11 (9‐14).

Seventy‐five (37%) patients had no varices, 64 (32%) had small varices and 56 (28%) had large oesophageal varices, whereas variceal status was unknown in 6 (3%) patients. Seventeen (9%) patients had a history of variceal bleeding, 85 (42%) had a history of or current ascites and 38 (19%) had a history of or current signs of hepatic encephalopathy. Median HVPG was 17 (12‐21) mm Hg. Twenty‐four (12%) patients had subclinical PHT (PH, ie 6‐9 mm Hg), 112 (56%) showed an HVPG between 10 and 19 mm Hg, and 65 (32%) had HRPH.

3.2. Severity of PHT {#liv14498-sec-0015}
--------------------

Patient characteristics were compared by stratification according to severity of PHT, ie HVPG 6‐9 mm Hg, 10‐19 mm Hg and ≥ 20 mm Hg (Table [1](#liv14498-tbl-0001){ref-type="table"}). Aetiologies of liver disease differed significantly among HVPG groups with a continuous increase in ALD prevalence with rising severity of PHT (17% among patients with 6‐9 mm Hg, 38% with 10‐19 mm Hg and 54% with ≥20 mm Hg, respectively; *P* = .021).

###### 

Patient characteristics stratified by severity of portal hypertension

  N = 201                                             HVPG 6‐9 mm Hg (n = 24)   HVPG 10‐19 mm Hg (n = 112)   HVPG ≥ 20 mm Hg (n = 65)   *P*‐value
  --------------------------------------------------- ------------------------- ---------------------------- -------------------------- ------------
  Age (y)                                             52.7 ± 2.3                56.8 ± 1.1                   58.4 ± 1.5                 0.129
  Sex (M, %)                                          16 (67)                   74 (66)                      45 (69)                    0.910
  Etiology (n, %)                                                                                                                       
  ALD                                                 4 (17)                    43 (38)                      35 (54)                    **.021**
  Viral                                               8 (33)                    21 (19)                      11 (17)                    
  Other                                               12 (50)                   48 (43)                      19 (29)                    
  Decompensation (n, %)                               1 (4)                     62 (55)                      53 (82)                    **\<.001**
  Varices (n, %)                                                                                                                        
  None                                                18 (75)                   41 (37)                      11 (17)                    **\<.001**
  Small                                               3 (13)                    25 (22)                      23 (35)                    
  Large                                               1 (4)                     43 (38)                      30 (46)                    
  (Unknown)                                           2 (8)                     3 (3)                        1 (1.5)                    
  Child score (points)                                5 (5‐5)                   6 (5‐7)                      7 (6‐9)                    **\<.001**
  MELD (points)                                       8 (7‐12)                  10 (9‐14)                    12 (10‐15)                 **\<.001**
  Creatinine (mg/dL)                                  0.73 (0.63‐0.87)          0.77 (0.59‐1.02)             0.71 (0.60‐0.97)           .847
  Sodium (mmol/L)                                     140 (139‐142)             139 (137‐141)                137 (134‐140)              **\<.001**
  Albumin (g/dL)                                      40.8 (37.3‐42.4)          37.2 (33.0‐40.7)             36.0 (30.2‐39.0)           **\<.001**
  INR                                                 1.2 (1.0‐1.3)             1.3 (1.2‐1.5)                1.4 (1.3‐1.6)              **\<.001**
  Platelets (g/L)                                     126 (90‐162)              99 (70‐137)                  96 (57‐126)                .056
  TE (kPa)[^a^](#liv14498-note-0002){ref-type="fn"}   16.3 (11.7‐20.4)          27.7 (17.0‐43.0)             62.2 (34.8‐75.0)           **\<.001**
  ELF score (points)                                  10.1 (9.6‐10.7)           11.2 (10.4‐12.3)             11.8 (11.1‐12.8)           **\<.001**
  TIMP1 (ng/mL)                                       251 (217‐301)             297 (244‐421)                409 (291‐495)              **\<.001**
  PIIINP (ng/mL)                                      11.5 (8.8‐16.2)           17.9 (10.8‐28.3)             20.6 (13.3‐33.1)           **\<.001**
  HA (ng/mL)                                          61.4 (43.4‐135.7)         195.1 (106.0‐392.4)          284.8 (174.9‐505.5)        **\<.001**

Abbreviations: (ALD) Alcohol‐related liver disease; (ELF) enhanced liver fibrosis score; (HA) Hyaluronic acid(HVPG) hepatic venous pressure gradient; (INR) International normalized ratio; (M) male gender; (MELD) Model for end‐stage liver disease score; (PIIINP) Amino‐terminal propeptide of type III procollagen; (TIMP‐1) Tissue inhibitor matrix metalloproteinase‐1; (VCTE) vibration‐controlled transient elastography.

*P*‐values \< .05 are indicated in bold.

Reliable TE results available in n = 21 (87.5%), n = 81 (72.3%) and n = 37 (56.9%) patients respectively.

John Wiley & Sons, Ltd

Expectedly, the proportion of patients with decompensated cirrhosis (dACLD) increased with rising severity of PH (4%, 55% and 82%, respectively; *P* \< .001). Consequently, median MELD and CTP score increased with HVPG (*P* \< .001). ELF score increased significantly across HVPG strata, with a median ELF of 10.1 (9.6‐10.7) in patients with an HVPG of 6‐9mm Hg, 11.2 (10.4‐12.3) with 10‐19mm Hg and 11.8 (11.1‐12.8) with ≥20 mm Hg (*P* \< .001).

3.3. Patient characteristics according to ELF score tertiles {#liv14498-sec-0016}
------------------------------------------------------------

Similarly, patient characteristics were compared after stratification by ELF score tertiles (T1‐T3): T1 was defined as ELF \< 10.76, T2 as ELF between 10.76 and 11.96 and T3 as ELF \> 11.96. CTP score and MELD increased in patients within higher ELF tertiles, as well as the proportion of patients with decompensation (all *P* ≤ .001; Table [2](#liv14498-tbl-0002){ref-type="table"}).

###### 

Patient characteristics stratified by enhanced liver fibrosis (ELF) scores

  N = 201                                             Tertile 1 (n = 67)   Tertile 2 (n = 67)   Tertile 3 (n = 67)   *P*‐value
  --------------------------------------------------- -------------------- -------------------- -------------------- ------------
  Age (y)                                             54.7 ± 1.3           59.0 ± 1.6           56.8 ± 1.3           .107
  Sex (M, %)                                          49 (73)              50 (75)              36 (54)              **.016**
  Etiology (n, %)                                                                                                    
  ALD                                                 12 (18)              31 (46)              39 (58)              **\<.001**
  Viral                                               23 (34)              9 (13)               8 (12)               
  Other                                               32 (48)              27 (40)              20 (30)              
  Decompensation (n, %)                               22 (33)              41 (61)              53 (79)              **\<.001**
  Varices (n, %)                                                                                                     
  None                                                31 (46)              16 (24)              23 (34)              **.036**
  Small                                               11 (16)              24 (36)              16 (24)              
  Large                                               22 (33)              26 (39)              26 (39)              
  (Unknown)                                           3 (5)                1 (1.5)              2 (3)                
  HVPG (mm Hg)                                        12 (9‐18)            18 (14‐21)           19 (16‐21)           **\<.001**
  Child score (points)                                5 (5‐5)              6 (5‐7)              8 (6‐10)             **\<.001**
  MELD (points)                                       9 (8‐12)             10 (9‐13)            14 (11‐17)           **\<.001**
  TE (kPa)[^a^](#liv14498-note-0004){ref-type="fn"}   18.8 (14.1‐28.1)     30.1 (19.4‐46.5)     48.0 (29.5‐70.0)     **\<.001**
  Creatinine (mg/dL)                                  0.77 (0.63‐0.96)     0.74 (0.59‐1.06)     0.67 (0.56‐0.90)     .222
  Sodium (mmol/L)                                     140 (138‐142)        138 (136‐140)        138 (135‐140)        **.001**
  Albumin (g/dL)                                      40.7 (38.7‐42.4)     37.1 (33.3‐40.1)     31.3 (28.1‐35.1)     **\<.001**
  INR                                                 1.2 (1.1‐1.4)        1.3 (1.2‐1.4)        1.5 (1.4‐1.7)        **\<.001**
  Platelets (g/L)                                     98 (65‐133)          105 (77‐141)         101 (76‐132)         .258

Abbreviations: ALD, alcohol‐related liver disease; ELF, enhanced liver fibrosis score; HVPG, hepatic venous pressure gradient; INR, international normalized ratio; M, male gender; MELD, model for end‐stage liver disease score; VCTE, vibration‐controlled transient elastography.

*P*‐values \< .05 are indicated in bold.

Reliable TE results available in n = 59 (87.5%), n = 49 (88.1%) and n = 53 (79.1%) patients, respectively.

John Wiley & Sons, Ltd

Furthermore, HVPG increased significantly across tertiles: median HVPG 12 (9‐18) mm Hg in T1, 18 (14‐21) mm Hg in T2 and 19 (16‐21) mm Hg in T3 (*P* \< .001). The presence of varices was significantly different between groups stratified by ELF tertiles in the overall cohort, however, a similar proportion of patients had large varices (33% vs 39% vs 39%, respectively; *P* = .036).

3.4. Correlation between ELF score and its single components with HVPG {#liv14498-sec-0017}
----------------------------------------------------------------------

ELF score and its single components correlated with HVPG in the overall cohort (Spearman\'s Rho 0.443, 0.32‐0.55; *P* \< .001; Figure [1A‐D](#liv14498-fig-0001){ref-type="fig"}). Among the single ELF components, HA displayed the strongest correlation with HVPG (Rho 0.419, 0.29‐0.53; Table [3](#liv14498-tbl-0003){ref-type="table"}, Table [S2](#liv14498-sup-0001){ref-type="supplementary-material"}).

![Correlation of enhanced liver fibrosis (ELF) score with hepatic venous pressure gradient (HVPG). Abbreviations: cACLD, compensated advanced chronic liver disease; dACLD, decompensated advanced chronic liver disease; ELF, enhanced liver fibrosis score; HA, hyaluronic acid; HVPG, hepatic venous pressure gradient; mm Hg, millimetres of mercury; PIIINP, amino‐terminal propeptide of type III procollagen; Rho, Spearman\'s Rho; TIMP‐1, tissue inhibitor matrix metalloproteinase‐1](LIV-40-1713-g001){#liv14498-fig-0001}

###### 

Correlation of enhanced liver fibrosis (ELF) score and its single components with hepatic venous pressure gradient (HVPG)

  Selection              Parameter   Rho               95%CI             *P*‐value
  ---------------------- ----------- ----------------- ----------------- ------------
  Overall (N = 201)      ELF         **0.443**         0.321‐0.551       **\<.001**
  TIMP1                  **0.368**   0.238‐0.485       **\<.001**        
  PIIINP                 **0.332**   0.199‐0.453       **\<.001**        
  HA                     **0.419**   0.294‐0.530       **\<.001**        
  ALD (N = 83)           ELF         **0.281**         0.063‐0.473       **.010**
  TIMP1                  **0.235**   0.014‐0.434       **.033**          
  PIIINP                 0.213       −0.010 to 0.415   .053              
  HA                     **0.283**   0.065‐0.475       **.010**          
  VIRAL (N = 40)         ELF         **0.449**         0.151‐0.673       **.004**
  TIMP1                  0.279       −0.045 to 0.550   .081              
  PIIINP                 **0.328**   0.009‐0.586       **.039**          
  HA                     **0.488**   0.200‐0.699       **.001**          
  OTHER (N = 78)         ELF         **0.391**         0.178‐0.569       **\<.001**
  TIMP1                  **0.323**   0.102‐0.514       **.004**          
  PIIINP                 0.197       −0.034 to 0.407   .084              
  HA                     **0.402**   0.191‐0.578       **\<.001**        
  HVPG 6‐9 (N = 24)      ELF         **0.569**         0.203‐0.796       **.004**
  TIMP1                  −0.147      −0.529 to 0.284   .493              
  PIIINP                 **0.559**   0.189‐0.790       **.005**          
  HA                     **0.475**   0.076‐0.743       **.019**          
  HVPG 10‐19 (N = 112)   ELF         **0.304**         0.120‐0.468       **.001**
  TIMP1                  **0.247**   0.058‐0.418       **.009**          
  PIIINP                 **0.273**   0.087‐0.441       **.004**          
  HA                     **0.268**   0.081‐0.437       **.004**          
  HVPG ≥ 20 (N = 65)     ELF         −0.023            −0.273‐0.229      .853
  TIMP1                  0.020       −0.232 to 0.270   .874              
  PIIINP                 −0.105      −0.347 to 0.149   .404              
  HA                     0.021       −0.231 to 0.271   .867              
  Child‐A (N = 116)      ELF         **0.450**         0.286‐0.588       **\<.001**
  TIMP1                  **0.261**   0.077‐0.438       **.005**          
  PIIINP                 **0.237**   0.052‐0.407       **.010**          
  HA                     **0.471**   0.311‐0.605       **\<.001**        
  Child‐B/C (N = 85)     ELF         0.014             −0.206 to 0.233   .896
  TIMP1                  0.129       −0.093 to 0.338   .241              
  PIIINP                 −0.003      −0.222 to 0.216   .979              
  HA                     −0.009      −0.227 to 0.211   .938              
  cACLD (N = 85)         ELF         **0.517**         0.335‐0.661       **\<.001**
  TIMP1                  **0.227**   0.062‐0.468       **.010**          
  PIIINP                 **0.291**   0.076‐0.479       **.007**          
  HA                     **0.535**   0.358‐0.675       **\<.001**        
  dACLD (N = 116)        ELF         0.113             −0.076 to 0.294   .227
  TIMP1                  **0.186**   −0.002 to 0.361   **.046**          
  PIIINP                 0.045       −0.144 to 0.231   .633              
  HA                     0.127       −0.062 to 0.307   .174              

Abbreviations: 95%CI, 95% confidence interval; ALD, Alcohol‐related liver disease; cACLD, compensated advanced chronic liver disease; dACLD, decompensated advanced chronic liver disease; ELF, enhanced liver fibrosis score; HA, hyaluronic acid; HVPG, hepatic venous pressure gradient; PIIINP, Amino‐terminal propeptide of type III procollagen; Rho, Spearman\'s Rho; TIMP‐1, Tissue inhibitor matrix metalloproteinase‐1.

*P*‐values \< .05 are indicated in bold.

John Wiley & Sons, Ltd

After stratifications according to ACLD aetiology, we specifically analysed correlations in patients with ALD and viral hepatitis. Median HVPG was higher in ALD than viral hepatitis patients (19 \[16‐21\] mm Hg vs 14 \[10‐20\] mm Hg, respectively; *P* = .001). The correlation coefficients were markedly lower in patients with ALD as compared to viral hepatitis or other aetiologies. PIIINP showed no significant association with HVPG in ALD patients, while TIMP1 did not correlate with HVPG in patients with viral hepatitis.

Similar correlation analyses of the HVPG and ELF were performed in subgroups according to severity of PHT: 6‐9 mm Hg, 10‐19 mm Hg and ≥20 mm Hg respectively. Interestingly, ELF score (Rho = 0.569, *P* = .004), PIIINP (Rho = 0.559; *P* = .005) and HA (Rho = 0.475, *P* = .019) showed the strongest correlation in patients with subclinical PHT. ELF score (Rho = 0.304, *P* = .001) and its single components significantly correlated with HVPG in stratum 10‐19 mm Hg, while no ELF parameter (eg ELF Rho = −0.023; *P* = .853) showed a meaningful correlation with HVPG in patients with HRPH.

Furthermore, patients were stratified by CTP stage and absence/presence of prior events of hepatic decompensation (Figure [1E,F](#liv14498-fig-0001){ref-type="fig"}). No correlation between ELF parameters and HVPG was found in patients with CTP stage B/C. Similarly, ELF showed no significant correlation in decompensated (dACLD) patients. Conversely, all parameters continuously increased with PHT severity in patients within CTP stage A and within cACLD patients. Again, in these patients with persevered liver function, ELF score (Rho = 0.450 for CTP‐A and Rho = 0.517 for cACLD; *P* \< .001, respectively) and HA (Rho = 0.471 for CTP‐A and Rho = 0.535 for cACLD; *P* \< .001, respectively) displayed the strongest association with HVPG.

3.5. Detection of clinically significant PHT by ELF {#liv14498-sec-0018}
---------------------------------------------------

AUROC analysis was performed to assess whether ELF score and/or its single components accurately detect CSPH (HVPG ≥ 10 mm Hg). In the overall study population, ELF displayed an AUROC of 0.833 (0.75‐0.92; *P* \< .001, Table [4](#liv14498-tbl-0004){ref-type="table"}). CSPH could be ruled‐out with an ELF cut‐off at \<9.7 with 97% sensitivity and 38% specificity. Ruling‐in of CSPH with ELF score ≥11.1 achieved 61% sensitivity and 92% specificity, with a PPV of 98%. The optimal single ELF cut‐off (by Youden\'s index) was 10.5, yielding 81% sensitivity and 75% specificity and PPV of 96% and NPV of 35% respectively. However, these ELF cut‐offs yielded relevant proportions of false‐positive and false‐negative rates (Table [S2](#liv14498-sup-0001){ref-type="supplementary-material"}).

###### 

Diagnostic accuracy of enhanced liver fibrosis (ELF) score and vibration‐controlled transient elastography (VCTE) for clinically significant portal hypertension (CSPH) and high‐risk portal hypertension (HRPH)

                                                AUROC       95%CI       *P*‐value    Cut‐off        SENS       SPEC       PPV        NPV        PLR        NLR
  --------------------------------------------- ----------- ----------- ------------ -------------- ---------- ---------- ---------- ---------- ---------- ----------
  CSPH---Overall cohort                                                                                                                                    
  ELF                                           **0.833**   0.75‐0.92   **\<.001**   Youden: 10.5   0.81       0.75       **0.96**   0.35       3.24       0.25
  In: 11.1                                      0.61        0.92        **0.98**     0.24           **7.63**   0.42                                        
  Out: 9.7                                      0.97        0.38        **0.92**     0.6            1.56       **0.08**                                    
  TE[^a^](#liv14498-note-0007){ref-type="fn"}   **0.834**   0.76‐0.91   **\<.001**   Youden: 23.2   0.70       0.95       **0.99**   0.36       **14.8**   0.31
  In: 23.2                                      0.70        0.95        **0.99**     0.36           **14.8**   0.31                                        
  Out: 11.8                                     0.95        0.29        0.88         0.5            1.33       0.18                                        
  CSPH---ALD                                                                                                                                               
  ELF                                           **0.978**   0.94‐1.00   **.001**     Youden: 10.3   0.95       1          **1**      0.5        ---        **0.05**
  In: 10.3                                      0.95        1           **1**        0.5            ---        **0.05**                                    
  Out: 9.9                                      0.99        0.5         **0.98**     0.67           1.98       **0.02**                                    
  CSPH---VIRAL                                                                                                                                             
  ELF                                           0.629       0.42‐0.84   0.265        ---            ---        ---        ---        ---        ---        ---
  CSPH---cACLD                                                                                                                                             
  ELF                                           **0.759**   0.64‐0.87   **\<.001**   Youden: 10.5   0.69       0.78       **0.90**   0.49       3.14       0.4
  In: 11.1                                      0.42        0.91        **0.93**     0.37           4.67       0.64                                        
  Out: 9.6                                      0.97        0.26        0.78         0.75           1.31       0.12                                        
  TE[^a^](#liv14498-note-0007){ref-type="fn"}   **0.743**   0.62‐0.86   **.002**     Youden: 23.2   0.59       0.95       **0.95**   0.5        **11.7**   0.43
  In: 23.2                                      0.59        0.95        **0.95**     0.5            **11.7**   0.43                                        
  Out: 11.8                                     0.89        0.30        0.75         0.55           1.27       0.36                                        
  HRPH---Overall cohort                                                                                                                                    
  ELF                                           **0.677**   0.60‐0.75   **\<.001**   Youden: 11.1   0.75       0.56       0.45       0.83       1.70       0.45
  In: 13.0                                      0.18        0.9         0.48         0.7            1.80       0.91                                        
  Out: 10.1                                     0.97        0.26        0.39         **0.95**       1.31       0.12                                        
  TE[^a^](#liv14498-note-0007){ref-type="fn"}   **0.813**   0.74‐0.89   **\<.001**   Youden: 27.4   0.92       0.59       0.45       **0.95**   2.23       0.14
  In: 67.1                                      0.43        0.91        0.64         0.82           4.9        0.62                                        
  Out: 27.4                                     0.92        0.59        0.45         **0.95**       2.23       0.14                                        

Abbreviations: 95%CI, 95% confidence interval; ALD, alcohol‐related liver disease; AUROC, area under the receiver operating characteristics; cACLD, compensated advanced chronic liver disease; CSPH, Clinically significant portal hypertension; ELF, enhanced liver fibrosis score; HRPH, high‐risk portal hypertension; NLR, negative likelihood ratio; PLR, positive likelihood ratio; VCTE, vibration‐controlled transient elastography.

*P*‐values \< .05, PPV and NPV ≥ 0.90, PLR \> 7 and NRL \< 0.1 are indicated in bold.

Reliable VCTE results available in n = 139 (69.2%) patients in the overall cohort, and n = 66 (77.6%) patients with cACLD.
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Among ELF single components, HA achieved the best performance with an AUROC of 0.828 (0.73‐0.92; *P* \< .001). In contrast, TIMP1 and PIIINP showed less diagnostic value to detect CSPH: AUROC 0.722 (0.63‐0.81; *P* \< .001) and 0.748 (0.66‐0.83; *P* \< .001) respectively (Table [S3](#liv14498-sup-0001){ref-type="supplementary-material"}).

Furthermore, AUROC was analysed by forming subgroups according to ACLD aetiology. In patients with ALD, ELF performed excellent regarding the detection of CSPH with an AUROC 0.978 (0.94‐1.00; *P* = .001, Table [4](#liv14498-tbl-0004){ref-type="table"}). Ruling‐out of CSPH with an ELF score \< 9.9 achieved 99% sensitivity, 50% sensitivity, 98% PPV and 67% NPV. ELF score ≥ 10.3 was the optimal cut‐off for ruling‐in CSPH (95% sensitivity, 100% specificity, 100% PPV and 50% NPV) in ALD patients. In contrast, ELF was not able to discriminate between subclinical PHT and CSPH in patients with viral hepatitis (AUROC 0.629; *P* = .265).

Finally, we assessed the predictive value for non‐invasive CSPH diagnosis in patients with cACLD (Table [2](#liv14498-tbl-0002){ref-type="table"}, Figure [2A](#liv14498-fig-0002){ref-type="fig"}). In this cohort, ELF AUROC was 0.759 (0.64‐0.87; *P* \< .001), with an optimal cut‐off at 10.5 that detected CSPH with 69% sensitivity, 78% specificity, 90% PPV and 49% NPV. Ruling‐in of CSPH in cACLD at an ELF score ≥11.1 had 93% PPV with 42% sensitivity and 91% specificity. Moreover, CSPH could be ruled‐out in cACLD patients by an ELF cut‐off at \<9.6 with 97% sensitivity, 26% specificity, 78% PPV and 75% NPV.

![Area under the receiver operating characteristics (AUROC) for detection of clinically significant portal hypertension (CSPH) and high‐risk portal hypertension (HRPH). (A) CSPH in patients with compensated liver disease (cACLD) and (B) HRPH in the overall cohort. Abbreviations: cACLD, compensated advanced chronic liver disease; CSPH, Clinically significant portal hypertension; ELF, Enhanced liver fibrosis score; HA, Hyaluronic acid; HRPH, High‐risk portal hypertension; PIIINP, Amino‐terminal propeptide of type III procollagen; TIMP‐1, Tissue inhibitor matrix metalloproteinase‐1](LIV-40-1713-g002){#liv14498-fig-0002}

In patients with cACLD, HA was the only single parameter suited to detect CSPH, with a slightly but non‐significantly better performance than ELF score: AUROC 0.787 (0.67‐0.90; *P* \< .001). Of note, among the single ELF components HA performed reasonable for CSPH prediction in cACLD, however, HA still had limited predictive value for ruling‐in and ruling‐out CSPH (Table [S3](#liv14498-sup-0001){ref-type="supplementary-material"} and Paragraph [S1](#liv14498-sup-0001){ref-type="supplementary-material"}).

3.6. Detection of high‐risk PHT by ELF {#liv14498-sec-0019}
--------------------------------------

Similar to AUROC analysis for detection of CSPH, we tested whether ELF and its components accurately detected HRPH (HVPG ≥ 20 mm Hg; Table [4](#liv14498-tbl-0004){ref-type="table"}). In the overall cohort, all parameters displayed statistically significant, however, weak potential for the non‐invasive diagnosis of HRPH: AUROC 0.677 (0.60‐0.75; *P* \< .001) for ELF, 0.673 (0.59‐0.75; *P* \< .001) for TIMP1, 0.625 (0.55‐0.71; *P* = .004) for PIIINP, and 0.663 (0.59‐0.74; *P* \< .001) for HA (Figure [2B](#liv14498-fig-0002){ref-type="fig"}). Non‐invasive ruling‐in of HRPH by ELF and its single components was suboptimal, however, ruling‐out of HRPH by an ELF score \< 10.1 yielded a NPV of 95% (39% PPV, 97% sensitivity and 26% specificity).

3.7. Detection of varices by ELF {#liv14498-sec-0020}
--------------------------------

Similarly, we performed an exploratory analysis whether ELF was able to detect the presence of any varices or varices needing treatment (VNT). Median time span between gastroscopy and hepatic vein catheterization was 0.9 (IQR 0.0‐2.6) months, and 55 (27%) patients had gastroscopy on the same day as HVPG/ELF measurement. However, ELF had no value for the detection of any varices or VNT as the AUROCs were only 0.580 (*P* = .065) and 0.552 (*P* = .228) respectively (Figure [S2](#liv14498-sup-0001){ref-type="supplementary-material"}).

3.8. Diagnostic value of vibration‐controlled transient elastography {#liv14498-sec-0021}
--------------------------------------------------------------------

Reliable VCTE results were obtained in 139 (69%) patients, with a median stiffness of 28.1 (17.6‐53.2) kPa. Stratified by PHT severity, median stiffness was 16.3 (11.7‐20.4) kPa in patients with HVPG 6‐9 mm Hg (n = 21, 88%), 27.7 (17.0‐43.0) kPa in patients with HVPG 10‐19 mm Hg (n = 81, 72%) and 62.2 (34.8‐75.0) kPa in patients with HVPG ≥ 20 mm Hg (n = 37, 57%; *P* \< .001 for stiffness comparison between HVPG strata), respectively (Table [1](#liv14498-tbl-0001){ref-type="table"}). Correlation between VCTE and ELF was Rho = 0.591 (95%CI 0.47‐0.69, *P* \< .001) and Rho = 0.668 (95%CI 0.56‐0.75, *P* \< .001) between VCTE and HVPG in the overall cohort (Figure [S3](#liv14498-sup-0001){ref-type="supplementary-material"}).

In the overall study cohort, VCTE AUROC was 0.834 (95%CI 0.76‐0.91, *P* \< .001; Figure S3) for prediction of CSPH, which was nearly identical to ELF (AUROC 0.833). In 66 cACLD patients, VCTE had an AUROC of 0.743 (95% CI 0.62‐0.86, *P* = .002), also being comparable to ELF (AUROC 0.759) for diagnosis of CSPH. Ruling‐out CSPH by VCTE at \<11.8 kPa achieved 94% sensitivity (29% specificity, PPV 88%, NPV 50%) in the overall cohort, and 89% sensitivity but only 55% NPV (30% specificity, 75% PPV) in cACLD patients. CSPH could be ruled‐in at \>23.2 kPa with 95% specificity (59% sensitivity, 99% PPV, 36% NPV) in the overall cohort, and 95% specificity and 95% PPV (70% sensitivity, 50% NPV) in cACLD.

4. DISCUSSION {#liv14498-sec-0022}
=============

This prospective study of 201 patients undergoing HVPG and simultaneous ELF score measurement is by now the largest analysis investigating whether the ELF score can adequately predict CSPH or HRPH in patients with ACLD, while also specifically investigating the diagnostic accuracy of ELF within compensated cirrhosis (cACLD).

ELF score comprises three serum parameters---TIMP1, PIIINP and HA---that reflect fibrosis and matrix remodelling.[^5^](#liv14498-bib-0005){ref-type="ref"} While the presence of advanced liver fibrosis is closely linked to the risk of PHT, additional dynamic components determine the severity of PHT and, thus, measurement of HVPG is the current diagnostic gold‐standard to detect CSPH.

The identification of non‐invasive predictors of CSPH represents an unmet clinical need for patients with cACLD [^18^](#liv14498-bib-0018){ref-type="ref"}, [^20^](#liv14498-bib-0020){ref-type="ref"} in order to facilitate therapeutic management. However, in patients with cACLD, several serum biomarkers that relate to liver fibrosis and PHT have not been evaluated in the setting of strictly cACLD or have only shown weak‐to‐moderate associations with HVPG, which limits their diagnostic value.[^25^](#liv14498-bib-0025){ref-type="ref"}, [^26^](#liv14498-bib-0026){ref-type="ref"}

Since studies have confirmed that ELF score accurately predicts liver fibrosis, ELF depicts an alternative to elastography‐based assessment of liver fibrosis, as recently demonstrated for NASH.[^8^](#liv14498-bib-0008){ref-type="ref"} However, along with restricted availability in non‐tertiary centres, elastography is sometimes limited by obesity and presence of ascites. Not surprisingly, it was also found that ELF single components relate to PHT.[^27^](#liv14498-bib-0027){ref-type="ref"}, [^28^](#liv14498-bib-0028){ref-type="ref"}, [^29^](#liv14498-bib-0029){ref-type="ref"} Interestingly, Thabut et al demonstrated that correlation of Fibrotest (which comprises five biomarkers related to fibrosis) with HVPG was markedly better (Pearson\'s *r* = .58) when including patients without PHT, while correlation was weak in patients with HVPG ≥ 6 mm Hg (Pearson\'s *r* = .23).[^30^](#liv14498-bib-0030){ref-type="ref"} However, the clinical value of this correlation of Fibrotest with HVPG in a population without PHT is limited. In contrast, our study assessed ELF only in patients with an HVPG ≥ 6mm Hg and in this setting, the ELF score showed a considerably stronger correlation with HVPG, as previously observed for Fibrotest. Still, we also observed a decrease in the correlation strength between ELF and its single components with increasing HVPG strata. Vizzutti et al reported similar findings for transient elastography, ie a weaker correlation between liver stiffness and HVPG in more pronounced PHT.[^31^](#liv14498-bib-0031){ref-type="ref"} Another study that primarily investigated whether quantitative magnetic resonance imaging could predict CSPH that also included patients without PHT, indicated an accurate correlation between ELF and HVPG (Pearson\'s *r* = .758), but no significant correlation was found in patients with CSPH.[^32^](#liv14498-bib-0032){ref-type="ref"}

Importantly, ELF, Fibrotest and elastography primarily reflect parameters related to hepatic fibrosis, while the development of hyperdynamic circulation that further aggravates PHT in patients with ACLD[^33^](#liv14498-bib-0033){ref-type="ref"}---and especially in decompensated cirrhosis (dACLD)---where the severity of PHT is not sufficiently captured by using fibrosis markers. This pathophysiological explanation was underlined by the lack of correlation between HVPG and ELF in our patients with HRPH.

Considering the diagnostic performance for CSPH screening of other non‐invasive fibrosis scores, the Fibrotest had an AUROC of 0.79 for detecting severe PHT (HVPG ≥12 mm Hg) in patients with cirrhosis,[^30^](#liv14498-bib-0030){ref-type="ref"} however, again as many as 14% of the included patients did not have PHT. Accordingly, mean/median HVPG was considerably lower[^30^](#liv14498-bib-0030){ref-type="ref"} than in our study.

A previous study (84% CSPH; 58% cACLD) showed that ELF score is able to predict CSPH, however, yielded a low AUROC of 0.68.[^15^](#liv14498-bib-0015){ref-type="ref"} Conversely, Sandahl et al showed that combining ELF with soluble CD163 achieved an AUROC of 0.91 to predict CSPH in a training cohort and an AUROC of 0.90 in a validation cohort.[^16^](#liv14498-bib-0016){ref-type="ref"} ELF alone (AUROC 0.88; 90% CSPH) performed slightly better in the study of Sandahl et al as compared to our study (ELF AUROC 0.833; 88% CSPH). Of note, we excluded patients who received concomitant treatment with NSBB at the time of HVPG measurement, while concomitant NSBB therapy was not an exclusion criterium in the study by Sandahl et al This selection criterium might be relevant since we previously found that liver stiffness (also a marker of "static fibrosis") and HVPG showed better correlation under NSBB therapy---which is explained by their inhibitory effect on the hyperdynamic circulation as the "dynamic" component or PHT.[^34^](#liv14498-bib-0034){ref-type="ref"}

Importantly, ELF was able to rule‐in CSPH at a cut‐off \>11.1 with a PPV of 98%. However, this ELF CSPH cut‐off requires validation in independent cohorts, since the related diagnostic indices may have been affected by the high prevalence of CSPH in our study population. Unfortunately, ELF cut‐offs for ruling‐out CSPH failed to provide clinically meaningful diagnostic value.

Of note, ELF showed an even better diagnostic accuracy for diagnosing CSPH in patients with ALD (AUROC 0.978), as compared to patients with viral hepatitis (AUROC 0.629), while the correlation between ELF and HVPG was considerably weaker in patients with ALD. This counterintuitive observation is explained by more pronounced severity of PHT in ALD patients, who simply had a very high pretest probability of CSPH as compared to viral liver disease. The high AUROC among ALD patients may, thus, be a consequence of the disproportionally high proportion of easy‐to‐classify patients with advanced disease in this subgroup. At the same time, there is a "loss‐of‐correlation" between ELF and HVPG in patients with CSPH (ie the higher HVPG strata), which explains the weaker correlation between ELF and HVPG in ALD patients, in whom CSPH was highly common. Accordingly, the observed differences in AUROC values are primarily a consequence of patient characteristics and should not be interpreted as evidence for aetiology‐dependent differences in the diagnostic performance of the test. Thus, differences in discriminative ability of ELF to detect CSPH in patients with ALD or viral liver disease cannot be fully answered by this study, mostly because of the limited number of ALD patients with only subclinical PHT.

While the ELF was of limited accuracy for ruling‐in HRPH, an ELF cut‐off \< 10.1 could, however, rule‐out HRPH with a high NPV of 95%. This finding may be useful for clinical decision‐making regarding TIPS implantation. For example, early or pre‐emptive TIPS implantation has shown favourable impact on patients with acute variceal bleeding (AVB),[^35^](#liv14498-bib-0035){ref-type="ref"} and is currently recommended in patients with AVB if the HVPG is ≥20 mm Hg.[^19^](#liv14498-bib-0019){ref-type="ref"} There also might be clinical applicability of ELF in patients with ascites evaluated for TIPS in order to assess if the refractoriness of ascites is mostly caused by HRPH. However, acute clinical events such as AVB or infections may impact on ELF score via dysregulation of ELF parameters. In our study, patients with acute decompensation and non‐elective admission at the time of HVPG measurement were excluded. Therefore, we think that ELF score yields best results for the diagnosis of HRPH (and also for CSPH) if the test is performed under stable conditions without acute decompensation or acute‐on‐chronic liver failure (ACLF).

Furthermore, liver stiffness measurement by VCTE had similar diagnostic value for prediction of CSPH as compared to ELF both in the overall cohort (AUROC 0.834 and 0.833 respectively) and patients with cACLD (AUROC 0.743 and 0.759 respectively). Previous elastography studies commonly reported better performance of VCTE for cACLD, however, this may be attributed to lower prevalence of CSPH.[^36^](#liv14498-bib-0036){ref-type="ref"}, [^37^](#liv14498-bib-0037){ref-type="ref"}, [^38^](#liv14498-bib-0038){ref-type="ref"}

Importantly, HA performed best in most analyses among all single ELF components, especially in patients with cACLD, which might be explained by its physical‐mechanical molecular properties. HA---as an essential component of liver ECM---might correlate more directly with the mechanical component of increased intrahepatic resistance than PIIINP and TIMP1. In contrast, PIIINP in serum was recently discussed to either reflect synthesis or degradation of type III collagen,[^39^](#liv14498-bib-0039){ref-type="ref"} while TIMP1 poses as a regulatory protein for proteinases that are involved in degradation of extracellular matrix.[^27^](#liv14498-bib-0027){ref-type="ref"}

Shortcomings of this study include the overrepresentation of patients with CSPH which may have impacted the cut‐off for differentiating between subclinical PHT and CSPH. Furthermore, there was a considerable rate of patients with prior decompensation in our study population, in whom the presence of CSPH is highly probable and the clinical relevance of non‐invasive tests for CSPH is less meaningful. However, the latter limitation was addressed by an additional analysis in the specific cohort of cACLD patients providing information regarding the diagnostic value of ELF for CSPH in the setting of compensated disease.

In summary, ELF significantly correlates with HVPG and may be used to rule‐in CSPH (cut‐off \> 11.1) and rule‐out HRPH (cut‐off \< 10.1). However, there remains a considerable diagnostic "grey area" where ELF cannot provide a clinically meaningful categorization of PHT severity and HVPG measurements are still necessary to diagnose CSPH.
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